Hepion Pharmaceuticals, Inc. (HEPA): רווח נקי למניה ב-12 החודשים האחרונים

Hepion Pharmaceuticals strictly adheres to environmental regulations regarding chemical disposal in its laboratories. Meanwhile, geopolitical instability complicates patent protection and global supplies, as clearly demonstrated by the annual net income per share chart, where the figure stood at -82.03. Business development is based on the strategic outsourcing of clinical trials for liver drugs through external contractors.
פילוחים אנליטיים של חברת Hepion Pharma (HEPA)

Analyzing the rolling earnings per share trend, we see the current state of the biotech issuer Hepion Pharmaceuticals (HEPA). This indicator reflects the net income remainder distributed across the total volume of issued securities for the year. The metric is sensitive to operating losses and the volume of equity capital. For a company in the liquidation stage following failed clinical trials, this figure captures the cash burn rate. The negative trend confirms a critical crisis in the business model.